Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to ...

A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces ...

The U.S. Centers for Medicare & Medicaid Services reported a request for information for a modernized digital health ...

Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve ...

Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to prevent the accumulation of substances ...

Just two months after Inozyme Pharma Inc. cut its workforce by 25% and prioritized activities to focus on a BLA filing for INZ-701 for ENPP1 deficiency, interim phase III data from its Energy 3 trial ...

Using a customized gene editing therapy, researchers at the Children’s Hospital of Philadelphia have reported success in treating an infant with a severe metabolic disorder. Kiran Musunuru, Barry J.

Royal Philips NV unveiled its Future Health Index report for 2025, and it reveals the widening trust gap between health care professionals and patients concerning the adoption of AI in health care.

Pancreatic cancer is one of the deadliest malignancies, with a 5-year overall survival rate of only 13%. Earlier studies demonstrated that the Lister strain of oncolytic vaccinia virus (VVL) is ...

PhaseV Inc. raised $50 million in a series A funding round to further develop its machine learning (ML) platform which helps companies reduce the cost and duration of clinical trials, and increase ...

Researchers at the China Pharmaceutical University have developed a series of highly active receptor-interacting protein kinase 1 (RIPK1) inhibitors with potent anti-inflammatory activity. RIPK1 is a ...

Newco Avidicure NV arrived on the scene with a hefty $50 million in seed funding to advance novel antibody formats the company says will surpass the best qualities of first-generation antibodies, ...